Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
Open accessThe DOI matches its Crossref record; 203 of the 203 references it cites were found in a registry or an index.
Abstract
The Clinical Practice Manual for Hepatocellular Carcinoma was published based on evidence confirmed by the Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma along with consensus opinion among a Japan Society of Hepatology (JSH) expert panel on hepatocellular carcinoma (HCC). Since the JSH Clinical Practice Guidelines are based on original articles with extremely high levels of evidence, expert opinions on HCC management in clinical practice or consensus on newly developed treatments are not included. However, the practice manual incorporates the literature based on clinical data, expert opinion, and real-world clinical practice currently conducted in Japan to facilitate its use by clinicians. Alongside each revision of the JSH Guidelines, we issued an update to the manual, with the first edition of the manual published in 2007, the second edition in 2010, the third edition in 2015, and the fourth edition in 2020, which includes the 2017 edition of the JSH Guideline. This article is an excerpt from the fourth edition of the HCC Clinical Practice Manual focusing on pathology, diagnosis, and treatment of HCC. It is designed as a practical manual different from the latest version of the JSH Clinical Practice Guidelines. This practice manual was written by an expert panel from the JSH, with emphasis on the consensus statements and recommendations for the management of HCC proposed by the JSH expert panel. In this article, we included newly developed clinical practices that are relatively common among Japanese experts in this field, although all of their statements are not associated with a high level of evidence, but these practices are likely to be incorporated into guidelines in the future. To write this article, coauthors from different institutions drafted the content and then critically reviewed each other’s work. The revised content was then critically reviewed by the Board of Directors and the Planning and Public Relations Committee of JSH before publication to confirm the consensus statements and recommendations. The consensus statements and recommendations presented in this report represent measures actually being conducted at the highest-level HCC treatment centers in Japan. We hope this article provides insight into the actual situation of HCC practice in Japan, thereby affecting the global practice pattern in the management of HCC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In general, European and US guidelines recommend more-restrictive criteria for resection than Asian guidelines7,22–27.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [23]
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Erdogan, D., Heijnen, B. H. M., Bennink, R. J., Kok, M., Dinant, S., Straatsburg, I. H., Gouma, D. J., & van Gulik, T. M. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00901.x · Cited by 11,700
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Self-citationA New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Self-citationCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Forner, A., Reig, M., & Bruix, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30010-2 · Cited by 5,531
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Cited by
Items 201–300 of 678
Ishihara, N., Komatsu, S., Sofue, K., Ueshima, E., Yano, Y., Fujishima, Y., Ishida, J., Kido, M., Gon, H., Fukushima, K., et al. (2024) · Hepatology Research · doi:10.1111/hepr.14024 · Cited by 11
“13 This gross morphological classification is usually used for posthepatectomy cases and has been reported to correlate with prognosis.”
Self-citationNishida, N. (2024) · Bioengineering · doi:10.3390/bioengineering11121243 · Cited by 18
Huang, X., Peng, G., Kong, Y., Cao, X., & Zhou, X. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s483208 · Cited by 11
“…can maintain elevated local concentrations of chemotherapeutic agents within tumors and has demonstrated efficacy for large, unresectable HCC. 6 7–9 Recently, systemic therapies incorporating molecular targeted agents (MTAs) and immunotherapy have significantly reshaped the management of…”
Lü, D., Li, H., Sun, P., Tian, J., Jiao, K., Cao, Q., Wang, Y., Jia, J., He, Q., Peng, S.-X., et al. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002326 · Cited by 14
“This finding suggested that even HAIC was added to the systemic regimens, too late tumor stage remained a substantial obstruction for improved survival outcomes [ 7 , 53 , 54 ] .”
Yamasaki, T., Saeki, I., Yamauchi, Y., Matsumoto, T., Suehiro, Y., Kawaoka, T., Uchikawa, S., Hiramatsu, A., Aikata, H., Kobayashi, K., et al. (2022) · Liver Cancer · doi:10.1159/000522389 · Cited by 12
Self-citationIwamoto, H., Shimose, S., Niizeki, T., Koga, H., Torimura, T., & The Kurume Liver Cancer Study Group of Japan (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0047 · Cited by 11
Summary of key guidelines for locoregional treatment of HCC in Asia, Europe, South and North America
Mónaco, R. G., Chung, J. W., Vilgrain, V., Bouattour, M., & Covey, A. M. (2022) · British Journal of Radiology · doi:10.1259/bjr.20220179 · Cited by 11
Iizuka, Y., Hiraoka, M., Kokubo, M., Sakamoto, T., Karasawa, K., Murofushi, K. N., Nakamura, M., Matsuo, Y., Morita, S., Inokuchi, H., et al. (2023) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2023.100591 · Cited by 11
“RFA cannot be used in tumors that are near blood vessels, intestines, or bile ducts [3,4].”
BackgroundPrognosis Prediction of Hepatocellular Carcinoma Based on Magnetic Resonance Imaging Features
Low, H. M., Lee, J. M., & Tan, C. H. (2023) · Korean Journal of Radiology · doi:10.3348/kjr.2023.0168 · Cited by 11
“Therefore, special consideration is required when administering locoregional treatments for these HCC subtypes as opposed to others [18].”
BackgroundHatanaka, T., Kakizaki, S., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6726 · Cited by 15
Self-citationZhu, S., Yu, Y., Yang, M., Liu, X., Lai, M., Zhong, J., Zhao, X., Lu, L., & Liu, Y. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2346624 · Cited by 11
Takamoto, T., Maruki, Y., & Kondo, S. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2229728 · Cited by 11
“Treatment options for HCC are outlined in national and international guidelines, with slight differences in the therapeutic approach between Asia [10], Europe [11], and North America [12].”
BackgroundShigematsu, Y., Amori, G., Tanaka, K., Kitahama, K., Kanda, H., Takahashi, Y., Takazawa, Y., Takeuchi, K., & Inamura, K. (2023) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-023-03568-9 · Cited by 11
Hiraoka, A., Kumada, T., Tada, T., Toyoda, H., Kariyama, K., Hatanaka, T., Kakizaki, S., Naganuma, A., Itobayashi, E., Tsuji, K., et al. (2023) · Liver Cancer · doi:10.1159/000530078 · Cited by 11
“First, since 2005, treatment has mainly followed the guidelines of the Japanese Society of Hepatology (JSH) [8 – 10], but the training cohort whose entire clinical course was analyzed belonged to a single institution.”
MethodSelf-citationWaked, I. A., Alsammany, S., Tirmazy, S. H., Rasul, K. I., Bani‐Issa, J., Abdel‐Razek, W., Omar, A., Shafik, A. G., Salem, S., Abdelaal, A. K., et al. (2023) · Liver International · doi:10.1111/liv.15685 · Cited by 11
Ishida, T., Mizumoto, M., Saito, T., Okumura, T., Miura, K., Makishima, H., Iizumi, T., Numajiri, H., Baba, K., Murakami, M., et al. (2024) · Cancers · doi:10.3390/cancers16112050 · Cited by 10
“Treatment of HCC generally includes surgery, transarterial chemoembolization (TACE), percutaneous ethanol injection (PEI), percutaneous microwave coagulation (PMC), and radiofrequency ablation (RFA) [3–9].”
BackgroundJiang, H., Li, B., Zheng, T., Qin, Y., Wu, Y., Wu, Z., Ronot, M., Chernyak, V., Fowler, K. J., Bashir, M. R., et al. (2024) · European Radiology · doi:10.1007/s00330-024-11295-1 · Cited by 12
Kan, X., Liang, B., Zhang, X., Yu, L., Luo, Y.-C., Zhou, S., Liu, R., Xu, G., Li, H., Liao, Z., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04159-y · Cited by 10
“The Japan Society of Hepatology (JSH) consensus recommends TACE for select patients with minor vascular invasion and for Child–Pugh class C patients (aged 65 years) who meet the Milan criteria (a single tumor up to 5 cm in diameter, or with ≤ 3 tumors up to 3 cm in diameter) [23].”
Tian, C., Wang, Z., Huang, L., Liu, Y., Wu, K., Li, Z., Han, B., Jiao, D., Han, X., & Zhao, Y. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03653-8 · Cited by 10
“The Japan Society of Hepatology (JSH) also nominated TAE as the golden standard of advanced HCC [8].”
BackgroundInfluentialOkubo, H., Ando, H., Takasaki, Y., Nakadera, E., Fukuo, Y., Shiina, S., & Ikejima, K. (2022) · Pharmaceuticals · doi:10.3390/ph15121460 · Cited by 10
Self-citationHuang, P., Ni, X., Zhou, C., Zhang, S., Wu, F., Xiao, Y., Yang, C., & Zeng, M. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s401027 · Cited by 10
Basic and translational research on carbon-ion radiobiology.
Sai, S., Koto, M., & Yamada, S. (2023) · PubMed Central · Cited by 15
Hiraoka, A., Kumada, T., Kariyama, K., Toyoda, H., Yasuda, S., Tsuji, K., Hatanaka, T., Kakizaki, S., Naganuma, A., Ishikawa, T., et al. (2021) · Oncology · doi:10.1159/000520292 · Cited by 12
Self-citationRen, Y., Guo, Y., Chen, L., Sun, T., Zhang, W., Sun, B., Zhu, L., Xiong, F., & Zheng, C. (2022) · Cancer Control · doi:10.1177/10732748221076806 · Cited by 10
Caviglia, G. P., Abate, M. L., Troshina, G., CARUCCI, P., Rolle, E., Risso, A., Burlone, M. E., Albè, A., Crevola, M., Musso, E. C., et al. (2023) · Biology · doi:10.3390/biology12010094 · Cited by 15
“Conversely, Eastern guidelines endorse the use of serum biomarkers [22,23]; the recommended cut-off value of PIVKA-II is 40 mAU/mL.”
BackgroundReal world for management of hepatocellular carcinoma: a large population-based study
Sethasine, S., Simasingha, N., Ratana-Amornpin, S., & Mahachai, V. (2023) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2023.2209686 · Cited by 10
Wu, J., Zhao, Q., Wang, Y., Fan, X. L., Cai, W., Liu, S., Du, Z., Yu, X., Liu, F., Yu, J., et al. (2023) · European Radiology · doi:10.1007/s00330-023-10006-6 · Cited by 9
“GPC-3 and Hepa were HCC-specific and well-recognized biomarker in pathologic examination, and Ki-67 was a proliferative biomarker in many types of tumor [24–26].”
Toshida, K., Itoh, S., Toshima, T., Yoshiya, S., Bekki, Y., Izumi, T., Iseda, N., Nakayama, Y., Ishikawa, T., & Yoshizumi, T. (2024) · Surgery Today · doi:10.1007/s00595-024-02914-x · Cited by 11
“…computed tomography (CT) or magnetic resonance imaging (MRI) of tumors that displayed vascular enhancement in the early phase and washout in the later phase, following the guidelines of the American Association for the Study of Liver Diseases and the Japan Society of Hepatology [14, 15].”
Hou, G., Zhang, F., Feng, X., Chen, Y., Zhang, J., & Wang, H. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s479810 · Cited by 10
Zhu, W., Qian, H., Cao, S., Xia, W., Wang, X., Jin, J., Wang, X., Zhang, H., Liu, D., & Chen, Y. (2024) · Analytica Chimica Acta · doi:10.1016/j.aca.2024.343533 · Cited by 11
Myeloid cell path to malignancy: insights into liver cancer
Ramirez, C. F. A., & Akkari, L. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.02.006 · Cited by 12
Lee, I., Wang, H.-W., Teng, W., Lin, T., Chen, C.-H., Lai, H., Lee, T., Chang, C.-W., Hung, C., Dai, C., et al. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0724 · Cited by 14
Vanderbecq, Q., Grégory, J., Dana, J., Burgio, M. D., Garzelli, L., Raynaud, L., Frémy, S., Paulatto, L., Bouattour, M., Kavafyan-Lasserre, J., et al. (2022) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2022.10.013 · Cited by 9
Furuichi, N., Naganuma, A., Kaburagi, T., Suzuki, Y., Hoshino, T., Shibusawa, N., Horiguchi, S., Hatanaka, T., Kakizaki, S., & Uraoka, T. (2023) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-023-01775-0 · Cited by 9
“Based on the results of the IMbrave 150 trial, the combination of atezolizumab, a programmed cell death ligand 1 (PD-L1) antibody, as well as bevacizumab, a vascular endothelial growth factor (VEGF) antibody, represents a novel first-line therapy in patients with HCC [5, 6].”
BackgroundYoshiya, S., Harada, N., Toshima, T., Toshida, K., Kosai‐Fujimoto, Y., Tomino, T., Nagao, Y., Kayashima, H., Itoh, S., & Yoshizumi, T. (2023) · Surgery Today · doi:10.1007/s00595-023-02710-z · Cited by 9
“Various treatment strategies for primary or recurrent HCC have been proposed, including liver resection, radiofrequency ablation, percutaneous ethanol injection therapy (PEIT), transcatheter arterial chem-oembolization (TACE), chemotherapy, and liver transplantation (LT) [2].”
Kim, H.-J., Lee, S. H., Shim, H. J., Bang, H. J., Cho, S., Chung, I., Hwang, E. C., Hwang, J., & Bae, W. K. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1265240 · Cited by 9
Tan, Z., Zhang, J., Xu, L., Wang, H., Mao, X., Zou, R., Wang, Q., Han, Z., Di, Z.-H., & Wu, D. (2023) · PLoS ONE · doi:10.1371/journal.pone.0290644 · Cited by 9
“In Japan, HAIC is recommended for HCC patients with major portal vascular invasion and in patients with intrahepatic multinodular lesions who are ineligible for hepatectomy, RFA, TACE [7].”
InfluentialIntermediate-stage hepatocellular carcinoma: refining substaging or shifting paradigm?
Stefanini, B., Ielasi, L., Pallotta, D. P., Penazza, S., Marseglia, M., & Piscaglia, F. (2024) · Journal of Liver Cancer · doi:10.17998/jlc.2024.02.21 · Cited by 9
“64-66 However, the shift in recommendations endorsed by Western scientific societies is particularly relevant.”
BackgroundKomatsu, S., Fujishima, Y., Kido, M., Kuramitsu, K., Goto, T., Yanagimoto, H., Toyama, H., & Fukumoto, T. (2021) · BMC Gastroenterology · doi:10.1186/s12876-021-02053-4 · Cited by 9
“Several promising phase 3 trials have been ongoing based on the favorable outcomes of phase 1/2 [4], and HCC treatment is now entering a new era with immunotherapy.”
BackgroundXu, Y., Fu, S., Shang, K., Zeng, J., & Ye, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.958869 · Cited by 10
Tse, J. R., Shen, L., Tiyarattanachai, T., Bird, K. N., Liang, T., Yoon, L. S., & Kamaya, A. (2022) · Abdominal Radiology · doi:10.1007/s00261-022-03681-4 · Cited by 9
Li, L., Liu, H.-T., Teng, Y., Deng, Z., Zhang, G.-L., Su, J., Ma, L., & Zhong, J. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2151891 · Cited by 12
“Although many guidelines make clear recommendations about second-line treatment options in HCC, so far there is no standard second-line treatment, especially for the case of sequential treatment after atezo+bev [2,17,19,21,23,27,28].”
BackgroundInfluentialLiu, C., Wu, S., Lai, L., Liu, J., Guo, Z., Ye, Z., & Chen, X. '. (2023) · BMC Bioinformatics · doi:10.1186/s12859-022-05091-1 · Cited by 9
“Currently, HCC is typically treated with liver resection, liver transplantation, thermal ablation, trans-arterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), personalized treatment, and immunotherapy [4, 5].”
BackgroundYi, C., Wei, W., Wan, M., Chen, Y., Zhang, B., & Wu, W. (2023) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-023-04443-8 · Cited by 9
Yu, W., Liu, W., Zhang, K., Chen, S., & Wang, X. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03511-6 · Cited by 9
“The available tyrosine kinase inhibitors and anti-Pd-1 antibodies in our hospital were sorafenib (Bayer, Germany), lenvatinib (Beacon Pharmaceuticals Ltd., Japan), apatinib (Jiangsu Hengrui Medicine Co., Ltd., People’s Republic of China), sindilizumab, camrelizumab, tislelizumab, and pembrolizumab.”
BackgroundInfluentialHanai, T., Nishimura, K., Unome, S., Miwa, T., Nakahata, Y., Imai, K., Suetsugu, A., Takai, K., & Shimizu, M. (2024) · Hepatology Research · doi:10.1111/hepr.14053 · Cited by 12
Kudo, M. (2022) · Liver Cancer · doi:10.1159/000525467 · Cited by 9
Self-citationKudo, M. (2023) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-23-122 · Cited by 8
Self-citationMorine, Y., Saito, Y., Yamada, S., Teraoku, H., Waki, Y., Noma, T., Ikemoto, T., & Shimada, M. (2023) · Hepatology Research · doi:10.1111/hepr.13887 · Cited by 8
“Regarding treatment guidelines for HCC, the Japan Society of Hepatology recommends that hepatic resection is introduced for HCC patients with fewer than three tumors, regardless of tumor size, and with macroscopic vascular invasion.(9,10) Furthermore, the Barcelona Clinic Liver Cancer (BCLC) staging system and treatme…”
MethodSelf-citationNakabori, T., Higashi, S., Abe, Y., Mukai, K., Ikawa, T., Konishi, K., Maeda, N., Nakanishi, K., Hasegawa, S., Wada, H., et al. (2024) · Current Oncology · doi:10.3390/curroncol31030117 · Cited by 10
“…endothelial growth factor antibodies, has significantly improved the prognosis of unresectable HCC compared to sorafenib [7,8]; therefore, an atezolizumab plus bevacizumab combinatorial treatment has been approved as a first-line systemic chemotherapy for unresectable HCC worldwide [3,9–11].”
BackgroundLi, J., Quan, B., Liu, W., Zhao, M., Fan, Y., Chen, R., Ren, Z., & Yin, X. H. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241231252 · Cited by 11
“8 A large-scale retrospective study reported HAIC had a significantly better prognosis compared with sorafenib in advanced HCC patients with macrovascular invasion.”
BackgroundWang, C., Leng, B., You, R., Yu, Z., Ya, L., Diao, L., Jiang, H., Cheng, Y., Yin, G., & Xu, Q. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s480540 · Cited by 11
“3,45 48 The response of HCC patients to sorafenib can be predicted using our TFS biomarker.”
The Role of AFP-L3 and DCP Biomarkers in the Diagnosis and Management of Hepatocellular Carcinoma
Norman, J. S., & Mehta, N. J. (2025) · Current Hepatology Reports · doi:10.1007/s11901-025-00686-7 · Cited by 11
Kudo, M., Ueshima, K., Tsuchiya, K., Yamashita, T., Shimose, S., Numata, K., Kodama, Y., Itoh, S., Tanaka, Y., Kuroda, H., et al. (2025) · Liver Cancer · doi:10.1159/000546899 · Cited by 17
“Based on this, Japanese guidelines currently recommend atezoli-zumab plus bevacizumab as first-line treatment for unresectable advanced-stage HCC that is not amenable to other locoregional therapies, including TACE [19].”
Self-citationTian, Y., Wang, J., Tian, G., Li, B., Chen, M., & Sun, X. (2022) · Frontiers in Surgery · doi:10.3389/fsurg.2022.848831 · Cited by 8
Modified CEUS LI-RADS using Sonazoid for the diagnosis of hepatocellular carcinoma
Sugimoto, K., Kamiyama, N., Kakegawa, T., Takahashi, H., Wada, T., Abe, M., Yoshimasu, Y., Takeuchi, H., & Itoi, T. (2023) · ULTRASONOGRAPHY · doi:10.14366/usg.23065 · Cited by 8
Horie, H., Ogiso, S., Yoh, T., Fukumitsu, K., Ishii, T., Omae, K., & Hatano, E. (2023) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-023-05802-w · Cited by 8
“The survival benefit of MTAs in patients with unresectable HCC is well accepted, 22–27 and in our RBM patients, SAR with MTA (without re-resection) was better than SAR with TACE only (18.1 vs. 6.8 months, p = 0.008).”
BackgroundInfluentialSelf-citationRole of TOP2A and CDC6 in liver cancer
Jia, W. P., Liu, X., & Zhang, Z. (2023) · Medicine · doi:10.1097/md.0000000000035604 · Cited by 12
“12] The etiology and biomarkers of liver cancer are not clear.”
BackgroundJiao, T., Tang, H., Zhang, W., Hu, B., Wan, T., Cao, Y., Zhang, Z., Wang, Y., Cao, J., Cui, M., et al. (2023) · BMC Surgery · doi:10.1186/s12893-023-02291-1 · Cited by 10
“PVTT was classified according to the Vp grading system [26].”
MethodYang, Z., Guan, R., Fu, Y., Hu, D., Zhou, Z., Chen, M., & Zhang, Y. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1336619 · Cited by 10
Zhao, Y., Bai, J. Y., Wang, X., Zhang, Y., Yan, X., Qi, J., Xia, X., Feng, Y., & Duan, B. (2024) · Journal of Cancer · doi:10.7150/jca.93885 · Cited by 9
“…protocols for liver function, tumor staging, and first-line treatment decisions in patients with rHCC are lacking, but treatment strategies from the Barcelona Clinical Liver Cancer (BCLC) and the Japanese Society of Liver Diseases can be extrapolated and used as treatment guidelines [9,10].”
MethodLiu, G., Zhu, D., He, Q., Zhou, C., He, L., Li, Z., Jiang, Z., Huang, M., Chang, B., & Wu, C. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s456460 · Cited by 9
“27 The evaluation of APS and its severity was conducted through DSA, and the APS grading system was derived from prior studies, 14,15 as follows: Shunt extending to the subsegmental portal branch was designated as Grade 1, indicating mild APS.”
MethodTransarterial chemoembolization for hepatocellular carcinoma with vascular invasion
Miyayama, S., Arai, Y., & Matsui, O. (2022) · British Journal of Radiology · doi:10.1259/bjr.20211316 · Cited by 10
Self-citationWu, Y., Zheng, S.-S., Zhang, Z., Chen, G., Chen, X., Zheng, T., Guo, X., Chen, H., Wang, M., Xie, X., et al. (2022) · Medicina · doi:10.3390/medicina58101343 · Cited by 8
“JSH consensus statements proposed that HAIC is another choice for patients with a liver function of Child–Pugh class B or worse at the time of TACE failure/refractoriness [41].”
BackgroundMa, Y., Jiang, X., Song, P., & Tang, W. (2024) · BioScience Trends · doi:10.5582/bst.2023.01436 · Cited by 11
Birgin, E., Hetjens, S., Tam, M. M., Correa‐Gallego, C., & Rahbari, N. N. (2023) · Cancers · doi:10.3390/cancers15082330 · Cited by 7
Kim, J. H., Kim, J. H., Yoon, H., Ko, G., Shin, J. H., Gwon, D. I., Ko, H. K., Chu, H. H., Kim, S. H., Kim, G. H., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1072922 · Cited by 7
Hepatocellular Carcinoma Surveillance
Koo, E., & Singal, A. G. (2023) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2023.06.005 · Cited by 9
Ashour, R., Rewisha, E. A., Rady, M. A., Elkhadry, S. W., Abdelhalim, H., & Atef, M. (2024) · BMC Cancer · doi:10.1186/s12885-024-13199-1 · Cited by 7
Su, J., Huang, D., Liu, S., Xu, X., Chen, S.-C., Ou, J., Li, J., Yang, T., Li, W. X., Fan, Y., et al. (2025) · Hepatology Research · doi:10.1111/hepr.14219 · Cited by 11
Wang, X., Luo, T., Lu, S.-L., Lu, H.-Z., Zhao, T.-Y., Jiang, Z.-J., Liu, X., Zhao, C., Li, L., & Chen, J. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e14816 · Cited by 7
RetractedYoh, T., Ishii, T., Ogiso, S., Nishino, H., Nishio, T., Koyama, Y., Uchida, Y., Ito, T., & Hatano, E. (2023) · Surgery · doi:10.1016/j.surg.2023.06.022 · Cited by 9
Self-citationNinomiya, M., Tsuruoka, M., Inoue, J., Hiraoka, A., Iwata, T., Sano, A., Sato, K., Onuki, M., Sawahashi, S., Kuroda, H., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-48068-7 · Cited by 7
“Therefore, sequential therapy of some MTAs or combination therapy with TACE and MTAs have been proposed in subpopulations of intermediate stage HCC 13,14 .”
MethodSelf-citationOkazaki, S., Shibuya, K., Shiba, S., Takura, T., & Ohno, T. (2024) · Advances in Radiation Oncology · doi:10.1016/j.adro.2024.101441 · Cited by 8
“3,6,7 However, many patients with HCC are ineligible for surgery and RFA owing to poor hepatic function or tumor size.”
Teng, Y., Li, Z., Liu, J., Teng, L., & Li, H. (2024) · Molecules · doi:10.3390/molecules29143360 · Cited by 7
Si, T., Shao, Q., Jassem, W., Ma, Y., & Heaton, N. D. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001889 · Cited by 7
Sun, L., Hu, Z., Xie, W., Yang, Z., Zeng, H., Zhang, Y., Chen, M., Hu, D., Zhou, Z., & Pan, Y. (2024) · BMC Cancer · doi:10.1186/s12885-024-12940-0 · Cited by 10
“1) criteria; [4] initially received either FOLFOX-HAIC monotherapy (HAIC group) or FOLFOX-HAIC plus ICIs and TKIs at the same course (ConHAIC group); and [5] at least received 1–2 courses of FOLFOX-HAIC.”
BackgroundMethodChen, S., Yuan, B., Yu, W., Wang, X., He, C., & Chen, C. (2022) · Journal of Surgical Oncology · doi:10.1002/jso.27023 · Cited by 7
“OR) was a safe and effective treatment for patients with unresectable HCC.11 Furthermore, a previous study showed that HAIC had a long overall survival (OS) than TACE in patients with unresectable large HCC.12 However, for patients with HCC with portal vein tumor thrombosis (PVTT), it is unknown which therapy is a bet…”
BackgroundMethodInfluentialDifferential Response to Sorafenib Administration for Advanced Hepatocellular Carcinoma
Huang, S.-F., Chong, S.-W., Huang, C.-W., Hsu, H.-Y., Pan, K., Hung, C., Wu, T., Lee, C., Hsieh, C., Wang, C., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10092277 · Cited by 7
Kato, N., Kudo, M., Tsuchiya, K., Hagihara, A., Numata, K., Aikata, H., Inaba, Y., Kondo, S., Motomura, K., Okano, N., et al. (2023) · Hepatology Research · doi:10.1111/hepr.13876 · Cited by 7
“Prior treatments other than sorafenib included the newly approved systemic therapies lenvatinib, regorafenib, and ramucirumab.(6,7,18,19) A favorable benefit–risk profile was demonstrated with cabozantinib in”
BackgroundMethodInfluentialSelf-citationUchida, Y., Yoh, T., Fukui, A., Takai, A., & Hatano, E. (2023) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000004570 · Cited by 7
Self-citationA Statistical Approach to the Diagnosis and Prediction of HCC Using CK19 and Glypican 3 Biomarkers
Burciu, C., Șirli, R., Bende, R., Popa, A., Vuletici, D., Miutescu, B. P., Rațiu, I., Popescu, A., Sporea, I., & Danilă, M. (2023) · Diagnostics · doi:10.3390/diagnostics13071253 · Cited by 7
“Conversely, the Asian [8,40] guidelines suggest the use of biomarkers.”
BackgroundYe, J., Lu, H.-Z., Zeng, C., Guo, L., Wang, X.-B., Chen, J., Bai, T., Wu, F., Mai, R., Guo, W., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12535-9 · Cited by 7
“…the BCLC (since 2018) [16], EASL (since 2012) [14], AASLD (since 2018) [15], NCCN (since 2009) [13], CNLC (since 2011) [3], JSH (since 2021) [19], and TLCA (since 2016) [18] had accepted hepatectomy to HCC, but merely expand minor hepatectomy to HCC patients with moderate CSPH and…”
BackgroundDuodenal Variceal Rupture during Atezolizumab and Bevacizumab Treatment for Hepatocellular Carcinoma
Tsuruoka, M., Inoue, J., Ouchi, K., Uno, K., Itami, H., Ninomiya, M., Iwata, T., Sano, A., Sato, K., Onuki, M., et al. (2022) · Internal Medicine · doi:10.2169/internalmedicine.0629-22 · Cited by 7
“Atezolizumab and bevacizumab (ATZ/BV) combination therapy is currently the first-line treatment for unresectable hepatocellular carcinoma (HCC) in Japan (1), based on the results of the IMbrave150 study (2).”
BackgroundInfluentialShigematsu, Y., Kanda, H., Takahashi, Y., Takeuchi, K., & Inamura, K. (2024) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-024-03939-w · Cited by 5
“Pathological features were evaluated according to the Japanese general rules for clinical and pathological study of primary liver cancer [20].”
Advances in systemic therapy leading to conversion surgery for advanced hepatocellular carcinoma
Hakoda, H., Ichida, A., & Hasegawa, K. (2024) · BioScience Trends · doi:10.5582/bst.2024.01372 · Cited by 14
Self-citationQuality of care in hepatocellular carcinoma—A critical review
Abdelmalak, J., Lubel, J. S., Sinclair, M. J., Majeed, A., Kemp, W. W., & Roberts, S. K. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000595 · Cited by 6
“[11,12,36] With a focus on maximizing survival even in patients at high risk for further recurrence, and the very limited availability of liver transplant, HCC experts in Asian countries believe that the narrow scope for resection in Western guidelines is not fit for purpose in their clinical…”
InfluentialHepatocellular Carcinoma: Imaging Advances in 2024 with a Focus on Magnetic Resonance Imaging
Renzulli, M., & Giampalma, E. (2025) · Current Oncology · doi:10.3390/curroncol32010040 · Cited by 8
“While awaiting updates to the EASL guidelines, we must contend with alternative guidelines, such as those from the Asia-Pacific Association for the Study of the Liver (APASL) [23] and the Japan Society of Hepatology [24].”
Mino, M., Kakazu, E., & Kanto, T. (2025) · Gut and Liver · doi:10.5009/gnl250187 · Cited by 7
Jiang, M., Chen, C., Hu, Y., Lin, G., & Li, H. (2025) · Scientific Reports · doi:10.1038/s41598-025-23027-6 · Cited by 12
Matono, T., Tada, T., Hiraoka, A., Hirooka, M., Nakamura, Y., Yoshida, O., Kariyama, K., Nouso, K., Tani, J., Morishita, A., et al. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70422 · Cited by 6
Self-citationNouso, K., Shiota, S., Fujita, R., Wakuta, A., Kariyama, K., Hiraoka, A., Atsukawa, M., Tani, J., Tada, T., Nakamura, S., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6416 · Cited by 5
Self-citationTakemura, Y., Endo, H., Hibi, T., Nakano, Y., Seishima, R., Takeuchi, M., Yamamoto, H., Maeda, H., Hanazaki, K., Taketomi, A., et al. (2024) · Hepatology Research · doi:10.1111/hepr.14014 · Cited by 6
“Hepatocellular carcinoma surveillance, which is important for the detection of resectable HCC, 18 temporarily decreased in 2020 because of social distancing and stay ‐ at ‐ home policies during the COVID ‐ 19 pandemic.”
BackgroundInfluentialOlbrich, A., Niemeyer, J., Seiffert, H., Ebel, S., Gros, O., Lordick, F., Forstmeyer, D., Seehofer, D., Rademacher, S., Denecke, T., et al. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05526-z · Cited by 6
“Response to TACE was defined according to the concept proposed by the Japanese Society of Hepatology (JSH) in 2021 (Kudo et al. 2021).”
BackgroundMethodRedefining HCC Surveillance in India: A Call for Innovative and Inclusive Strategies
Yelsangikar, A., & Patil, P. S. (2024) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2024.101474 · Cited by 6
Gupta, M., Davenport, D. L., Orozco, G., Bharadwaj, R. R., Roses, R. E., Evers, B. M., Zwischenberger, J. B., Ancheta, A., Shah, M. B., & Gedaly, R. (2024) · Surgical Oncology · doi:10.1016/j.suronc.2024.102114 · Cited by 6
Yoon, J. K., Han, D. H., Lee, S., Choi, J., Choi, G. H., Kim, D. Y., & Kim, M. (2024) · Liver International · doi:10.1111/liv.16059 · Cited by 6
Embolic and Ablative Therapy for Hepatocellular Carcinoma
Khalid, M., Likhitsup, A., & Parikh, N. D. (2024) · Clinics in Liver Disease · doi:10.1016/j.cld.2024.08.003 · Cited by 6
Giuliante, F., Famularo, S., Grasselli, S., Sangiovanni, A., Vitale, A., Cabibbo, G., Lauterio, A., Cipriani, F., Saccomandi, A., Arru, M., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101420 · Cited by 6
“14,15 10 However, the heterogeneity of the enrolled patients in terms of tumor burden, tumor location, or vascular contact, does not permit to achieve a solid evidence-based indication guiding the treatment decision in clinical practice.”
Huang, L., Xu, Y., Liu, N., Chen, H., Wu, Z., Li, Q., Lu, M.-Q., Wei, W., Zhang, Y., Chen, M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1573098 · Cited by 7
Metadata
- Authors
- Kudo, M., Kawamura, Y., Hasegawa, K., Tateishi, R., Kariyama, K., Shiina, S., Toyoda, H., Imai, Y., Hiraoka, A., Ikeda, M., Izumi, N., Moriguchi, M., Ogasawara, S., Minami, Y., Ueshima, K., Murakami, T., Miyayama, S., Nakashima, O., Yano, H., Sakamoto, M., Hatano, E., Shimada, M., Kokudo, N., Mochida, S., Takehara, T., & HCC Expert Panel of the Japan Society of Hepatology
- Affiliations
- Kindai University Hospital (JP)
- Toranomon Hospital (JP)
- The University of Tokyo (JP)
- Okayama City Hospital (JP)
- Juntendo University (JP)
- Ogaki Municipal Hospital (JP)
- Ikeda Municipal Hospital (JP)
- Ehime Prefectural Central Hospital (JP)
- National Cancer Center Hospital East (JP)
- Musashino Red Cross Hospital (JP)
- Kyoto Prefectural University of Medicine (JP)
- Chiba University (JP)
- Kobe University (JP)
- Fukui-ken Saiseikai Hospital (JP)
- Kurume University (JP)
- Keio University (JP)
- Hyogo Medical University (JP)
- Tokushima University (JP)
- National Center for Global Health and Medicine (JP)
- Saitama Medical University (JP)
- The University of Osaka (JP)
- ORCID
- Kudo, Masatoshi
- Kawamura, Yusuke
- Hasegawa, Kiyoshi
- Tateishi, Ryosuke
- Kariyama, Kazuya
- Shiina, Shuichiro
- Toyoda, Hidenori
- Hiraoka, Atsushi
- Ikeda, Masafumi
- Izumi, Namiki
- Moriguchi, Michihisa
- Ogasawara, Sadahisa
- Minami, Yasunori
- Ueshima, Kazuomi
- Murakami, Takamichi
- Miyayama, Shiro
- Nakashima, Osamu
- Yano, Hirohisa
- Sakamoto, Michiie
- Hatano, Etsuro
- Shimada, Mitsuo
- Kokudo, Norihiro
- Mochida, Satoshi
- Takehara, Tetsuo
- Venue
- Liver Cancer
- Publisher
- S. Karger AG
- Published
- 2021
- Volume
- 10
- Issue
- 3
- Pages
- 181-223
- ISSN
- 1664-5553 (ISSN-L)
- 2235-1795
- PMC
- PMC8237791
- OpenAlex
- W3162270595
- Cited by
- 678
- References
- 200
- Citations by year
- 2026: 78 · 2025: 137 · 2024: 158 · 2023: 177 · 2022: 108 · 2021: 17
- FWCI
- 14.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (vor)
- creativecommons.org/licenses/by-nc/4.0/ (tdm)
- Locations
- Liver Cancer (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc)
- Funders
- Japan Society for the Promotion of Science (19K08199)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Keywords
- hepatocellular carcinoma, consensus statement, clinical guidelines, HCC diagnosis, HCC treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.